Literature DB >> 9737722

Identification and expression of a novel isoform of cAMP response element modulator in the human heart.

F U Müller1, P Bokník, J Knapp, J Neumann, U Vahlensieck, E Oetjen, H H Scheld, W Schmitz.   

Abstract

In end-stage human heart failure, excessive beta-adrenergic stimulation of the cAMP-dependent signaling pathway due to enhanced endogenous catecholamines is hypothesized to contribute to expressional alterations of myocardial regulatory proteins. The cAMP response element modulator (CREM) regulates the transcription of cAMP-responsive genes and might be involved in the regulation of cardiac gene expression. Using the reverse transcription polymerase chain reaction, we identified a novel CREM mRNA, CREM-Ib deltaC-X, in the human heart. Overexpression of CREM-Ib deltaC-X decreased cAMP response element (CRE) -mediated gene transcription in HIT-T15 cells, and this activity was assigned to the part of the sequence encoding putative internally translated proteins. Two of three possible internally translated proteins were immunologically identified in cells overexpressing CREM-Ib deltaC-X tagged with the hemagglutinin epitope of the influenza virus. Both proteins were expressed in bacteria and showed CRE-specific DNA binding, formation of heterodimers with the cAMP response element binding protein (CREB), and inhibition of CREB's binding to the CRE. CREM expression was detected on the mRNA and protein levels in the human heart. We conclude that CREM-Ib deltaC-X generates internally translated repressors of CRE-mediated gene transcription, suggesting the first example for the existence and function of human cardiac CREM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737722     DOI: 10.1096/fasebj.12.12.1191

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

Review 1.  Transcriptional regulation by cAMP in the heart.

Authors:  F U Müller; J Neumann; W Schmitz
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 2.  Control of cardiomyocyte gene expression as drug target.

Authors:  H Rupp; M Benkel; B Maisch
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

3.  Phosphoprotein abundance changes in hypertensive cardiac remodeling.

Authors:  Kumar Kotlo; Keven R Johnson; Jean M Grillon; David L Geenen; Pieter deTombe; Robert S Danziger
Journal:  J Proteomics       Date:  2012-05-31       Impact factor: 4.044

4.  The CREB leucine zipper regulates CREB phosphorylation, cardiomyopathy, and lethality in a transgenic model of heart failure.

Authors:  Gordon S Huggins; John J Lepore; Sarah Greytak; Richard Patten; Rachel McNamee; Mark Aronovitz; Paul J Wang; Guy L Reed
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-06       Impact factor: 4.733

5.  Long-term methionine-diet induced mild hyperhomocysteinemia associated cardiac metabolic dysfunction in multiparous rats.

Authors:  Su Song; Elizabeth Kertowidjojo; Caroline Ojaimi; Beatriz Martin-Fernandez; Sharath Kandhi; Michael Wolin; Thomas H Hintze
Journal:  Physiol Rep       Date:  2015-05

6.  Global comparison of phosphoproteins in human and rodent hearts: implications for translational studies of myosin light chain and troponin phosphorylations.

Authors:  K Kotlo; A M Samarel; H Y Chen; J Aldstadt; R S Danziger
Journal:  Springerplus       Date:  2016-06-21

7.  Homozygous CREM-IbΔC-X Overexpressing Mice Are a Reliable and Effective Disease Model for Atrial Fibrillation.

Authors:  Frank T Stümpel; Juliane Stein; Kirsten Himmler; Beatrix Scholz; Matthias D Seidl; Boris V Skryabin; Frank U Müller
Journal:  Front Pharmacol       Date:  2018-07-05       Impact factor: 5.810

8.  Cardiac expression of the CREM repressor isoform CREM-IbΔC-X in mice leads to arrhythmogenic alterations in ventricular cardiomyocytes.

Authors:  J S Schulte; E Fehrmann; M A Tekook; D Kranick; B Fels; N Li; X H T Wehrens; A Heinick; M D Seidl; W Schmitz; F U Müller
Journal:  Basic Res Cardiol       Date:  2016-01-27       Impact factor: 17.165

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.